Presidential Decision Directive 67

Presidential Decision Directive 67
Name	Presidential Decision Directive 67
Date	1998
Issued by	Bill Clinton
Classification	Classified (originally)
Topics	biodefense, public health policy

Contents

Presidential Decision Directive 67 was a United States national security directive issued in 1998 under President Bill Clinton addressing aspects of biodefense, public health preparedness, and coordination among federal agencies. It set out roles, responsibilities, and interagency mechanisms involving entities such as the Department of Defense, Department of Health and Human Services, and the Federal Bureau of Investigation to respond to biological threats and incidents. The directive intersected with policies and programs tied to national security, homeland security, and emergency response frameworks shaped by actors including the National Security Council, Centers for Disease Control and Prevention, and National Institutes of Health.

Background

The directive emerged amid heightened concern following events such as the Aum Shinrikyo attacks, the 1995 Oklahoma City bombing, and evolving threats associated with state and non-state biological research programs like those linked historically to Iraq and Soviet Union. Debates involving figures from the Armed Forces Epidemiological Board, Office of Science and Technology Policy, and congressional committees including the Senate Select Committee on Intelligence framed discussions about biodefense after incidents such as the 1995 Ebola virus outbreak in Kikwit and the growing awareness of advances by institutions like the Centers for Disease Control and Prevention and the Johns Hopkins Bloomberg School of Public Health. Policy development was influenced by prior directives such as Presidential Decision Directive 39 and legislative initiatives involving the Biological Weapons Convention and appropriations overseen by the House Committee on Appropriations.

Key provisions delineated roles for agencies including the Department of Health and Human Services, Department of Defense, Department of Energy, Federal Bureau of Investigation, and the Environmental Protection Agency in areas of detection, attribution, consequence management, and medical countermeasure development. The directive emphasized research coordination with institutions such as the National Institutes of Health, Food and Drug Administration, and academic centers like Harvard Medical School and University of California, Berkeley to accelerate diagnostics and vaccines. It directed interagency mechanisms for information sharing among the National Security Council, Central Intelligence Agency, and the Federal Emergency Management Agency to streamline intelligence support, incident response, and logistical operations drawing on capacities from organizations including the United States Postal Service and Centers for Disease Control and Prevention laboratories.

Implementation required operational planning by the Department of Defense components including United States Army Medical Research Institute of Infectious Diseases and collaboration with civilian agencies such as the Department of Health and Human Services’s Centers for Disease Control and Prevention and the Food and Drug Administration. Law enforcement responsibilities engaged the Federal Bureau of Investigation and the Department of Justice, while scientific coordination involved the National Institutes of Health, the National Science Foundation, and national laboratories such as Los Alamos National Laboratory and Oak Ridge National Laboratory. International liaison elements referenced partnerships with organizations like the World Health Organization, the Pan American Health Organization, and allied ministries in countries including United Kingdom, France, and Germany for surveillance and response interoperability.

The directive influenced subsequent programs including biodefense funding streams, public health preparedness exercises involving Operation Dark Winter and policy shifts evident after the 2001 anthrax attacks which implicated postal processing centers and anniversaries of events such as the 1993 World Trade Center bombing. Controversies arose over classification levels, civil liberties concerns voiced by advocates connected with institutions like the American Civil Liberties Union and oversight debates in the United States Congress. Academic and media scrutiny from outlets linked to campuses such as Massachusetts Institute of Technology and journals associated with The Lancet and Science (journal) questioned transparency, dual-use research governance, and coordination gaps highlighted by reviews in bodies like the Government Accountability Office and panels convened by the National Academy of Sciences.

Portions of the directive remained classified for years, prompting freedom of information discussions involving the American Civil Liberties Union and litigation invoking statutes like the Freedom of Information Act with filings in courts including the United States District Court for the District of Columbia. Redacted summaries and related materials were later reviewed in congressional hearings chaired by members of the Senate Armed Services Committee and House Committee on Homeland Security, and informed public reports by think tanks such as the Brookings Institution, Rand Corporation, and Center for Strategic and International Studies. Declassification debates intersected with broader policy reforms in biodefense during administrations including those of George W. Bush, Barack Obama, and influenced frameworks implemented by the Department of Health and Human Services and the Department of Homeland Security.

Category:United States national security directives